| Literature DB >> 35631494 |
Yanqi Huang1, Lin Cao1, Bogdan V Parakhonskiy1, Andre G Skirtach1.
Abstract
Because free therapeutic drug molecules often have adverse effects on normal tissues, deliver scanty drug concentrations and exhibit a potentially low efficacy at pathological sites, various drug carriers have been developed for preclinical and clinical trials. Their physicochemical and toxicological properties are the subject of extensive research. Inorganic calcium carbonate particles are promising candidates as drug delivery carriers owning to their hardness, porous internal structure, high surface area, distinctive pH-sensitivity, low degradability, etc, while soft organic alginate hydrogels are also widely used because of their special advantages such as a high hydration, bio-adhesiveness, and non-antigenicity. Here, we review these two distinct substances as well as hybrid structures encompassing both types of carriers. Methods of their synthesis, fundamental properties and mechanisms of formation, and their respective applications are described. Furthermore, we summarize and compare similarities versus differences taking into account unique advantages and disadvantages of these drug delivery carriers. Moreover, rational combination of both carrier types due to their performance complementarity (yin-&yang properties: in general, yin is referred to for definiteness as hard, and yang is broadly taken as soft) is proposed to be used in the so-called hybrid carriers endowing them with even more advanced properties envisioned to be attractive for designing new drug delivery systems.Entities:
Keywords: alginate hydrogels; calcium carbonate; drug delivery; drug loading; release mechanism
Year: 2022 PMID: 35631494 PMCID: PMC9146629 DOI: 10.3390/pharmaceutics14050909
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Figure 1An overview of inorganic and organic drug delivery carriers including calcium carbonate and alginate carriers (above). Similarities and differences (yin-&-yang properties) between CaCO3 and alginate and their respective attributes (below).
Figure 2The crystal structure and macroscopic morphology (obtained from a scanning electron microscope (SEM)) of three crystalline phases of CaCO3 particles: calcite (top), vaterite (middle), and aragonite (bottom).
Figure 3Schematic illustration of proposed mechanisms of the CaCO3 formation. Reproduced with permission from [53], John Wiley & Sons—Books, 2020. (PNCs: prenucleation clusters; ACC: amorphous CaCO3).
Studies on the application of CaCO3-based carriers in drug delivery.
| Particles | Loading Method | Particle Size | Loaded Drug | Loading | Release Mechanism and Major Effect |
|---|---|---|---|---|---|
| CaCO3 | Physical | 400–600 nm | Rh6G/TD4 [ | 0.8–15.7% | Phase-induced release; sustained release effect; pH dependent |
| 0.8–5 μm | Alkaline phosphatase [ | ||||
| 20 and 80 nm | μRNA [ | ||||
| 17.9 μm | Ibuprofen; losartan potassium; metronidazole benzoate; nifedipine [ | 25–50% | Surface effects and diffusion | ||
| Co-precipitation | 113 nm | Catalase [ | 20% | pH dependent; | |
| Microcapsules | Physical | 2–3 μm | DQ−ovalbumine [ | Good encapsulation effect and activity protection | |
| Lactoferrin [ | |||||
| Heparin/CaCO3/CaP | 112–384 μm | DOX [ | 1.4–1.9% | Concentration gradient; diffusion driving force; | |
| Cellulose-based CaCO3 | 2–3.5 μm | Lovastatin (LOV) [ | 12.5% | ||
| Protamine sulfate and sodium poly(styrene sulfonate)/CaCO3 | 5 μm | Ibuprofen [ | 4.5% | ||
| Cyclodextrin/CaCO3 | 4–6 µm | 5-Fluorouracil; Na-L-thyroxine [ | |||
| ACC/poly(acrylic acid) | Co-precipitation | 62 nm | DOX [ | >9% | |
| Mucin/CaCO3 | 5.8 μm | DOX; aprotinin; insulin [ | 13%, 10%, 80% | Mucin content dependent; phase-induced release |
Figure 4Factors influencing the loading capacity of CaCO3 particles via physical adsorption including particle properties (size, surface area, charge, shape), loading parameters (mechanical and ultrasound agitation, freezing, loading time, concentration), molecular weight of drugs (under 1 kDa and over 1 kDa).
Figure 5Capsule recrystallization in a medium. Panels (a,b) represent a scheme of the release mechanism and the corresponding container two-photon microscope fluorescence images with scanning electron microscopy (SEM) images as insets. (a) The carriers are in a pure vaterite phase with all dye encapsulated; panel (b) shows the calcite phase, where the dye was released into the medium apart from residuals attached to the crystal surfaces. Panel (c) displays dye release curves for different payloads measured by spectrofluorometry during the immersion in water and in ethanol. Panels (a–c) are reproduced with permission from [70], the Royal Society of Chemistry, 2013; panel (d) schematics of the degradation of particles due to pH changes. Reproduced with permission from [73], Elsevier, 2013. Panel (e) depicts release of the perphenazine. Reproduced with permission from [74], Elsevier, 2021.
Figure 6Coated CaCO3 nanoparticles were prepared using the LbL method for the targeted delivery and controlled release of drug molecules. Reproduced with permission from [115], Hindawi (open access), 2020. (DOX: doxorubicin; CS: chitosan; SA: sodium alginate; FA: folic acid; GA: glutaraldehyde; PEG: poly(ethylene glycol); EDC: N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide; NHS: N-hydroxysuccinimide).
Figure 7Schematic showing the gelation mechanism of alginate prepared using different methods. (A) Ionic crosslinking (Left); egg-box model of alginate gelation (Right). Reproduced with permission from [134], Elsevier, 2020; (B) covalent crosslinking; (C) cell crosslinking; (D) enzymatic crosslinking; (E) phase transition; (F) free radical polymerization. Reproduced with permission from [28,30], MDPI, 2013; Springer Nature, 2020.
Alg-based hydrogels prepared by ionic and covalent crosslinking, their properties, and applications.
| Materials | Active Ingredient | Properties | Applications | Ref | |
|---|---|---|---|---|---|
| Ionic | Alg + CaCl2 | Extracellular vesicles/ | High encapsulation rate, sustained releasee, high plasticity | Enhances cardiac function and drug bioavailability; oral tissue reparation | [ |
| Alg + CS + SrCl2 | Chondroitin sulfate | Lower water retention capacity | Facilitate proliferation of osteoblasts; modulate osteogenic factors | [ | |
| Alg + Ag | Silver nanoparticles, BSA, tannic acid | Remote release, sensorics function, antibacterial properties | Oral delivery | [ | |
| Alg + Pectin + CaCl2 | Simvastatin | Sustained release | Promote angiogenesis, collagen synthesis and wound healing | [ | |
| Alg + CaCO3 + | Hyaluronic acid | Biocompatibility | Wound healing | [ | |
| Covalent crosslinking | Alg-Poloxamer + Silk fibroin | Porous, thermosensitive, | Cartilage tissue engineering. | [ | |
| Alg + Chitosan + Gelatin | Tetracycline hydrochloride | Biodegradable | Antibacterial; wound healing | [ | |
| Alg + Chitosan | Deferoxamine; | Sustained release biodegradable, high mechanical properties | Delivery system; | [ | |
| Alg + Sericin | Naproxen | Higher loading capacity and stability, sustainable release | Drug delivery | [ | |
| Alg-norbornene | Doxorubicin | Tunable porosity | Controlled drug release | [ | |
| Alg | - | High toughness and electric conductivity | Antiseptic | [ |
The properties, and functions of Alg-based hydrogels prepared by free radical polymerization.
| Materials | Initiators | Active Ingredient | Properties | Functions | Ref |
|---|---|---|---|---|---|
| Alg-2-acrylamido-2-methyl propane sulphonic acid | Ammonium peroxodisulfate | Diclofenac sodium | pH-independent swelling | Sustained delivery | [ |
| Alg + PVA | 2-Acylamido-2-methylpropane-sulfonic acid | Tramadol HCl | pH-independent swelling | Controlled drug release | [ |
| Alg-acrylamide | Ammonium persulfate Sodium metabisulfite | Acetaminophen drugs | pH sensitivity | Drug release | [ |
| Alg-2-acrylamidoglycolic acid | Potassium peroxydiphosphate | - | Biodegradability | - | [ |
| Alg-methacrylic anhydride | UV light | Hyaluronic acid | Injectable | Support stem cell chondrogenesis | [ |
| Alg-glycidyl | Ammonium persulfate | - | Porous structure | Encapsulate umbilical vein endothelial cells | [ |
| Alg-2-hydroxyethyl | Potassium persulfate | Bovine albumin serum | pH sensitivity | High osteoblastic cell viability and proliferation | [ |
Various CaCO3-based carriers used in drug delivery.
| Delivery Types | Carriers | Drug | Properties |
|---|---|---|---|
| Oral | CaCO3 particles | Arginine [ | Satisfying drug efficacy; |
| CaCO3-based stabilized Pickering emulsion | Vitamin D3 [ | Satisfying stability and bioavailability | |
| Colon | CaCO3 particles | 5-fluorouracil (5-FU) and natural compound indole-3-carbinol (I3C) [ | High loading capacity; sustainable release; low side effects |
| CaCO3-Nanocellulose Films | 5-Fluorouracil [ | ||
| Pectin–chitin/CaCO3 | Fosamax [ | Adequate swelling, degradation, protein adsorption properties | |
| Transdermal | CaCO3 particles | Cyanine 7 (Cy7) dye [ | High loading capacity; sustainable release; low side effects; effective penetration effect |
| Intravenous | CaCO3 particles | DOX and alkylated NLG919 [ | Enhanced chemo-immunotherapy of cancer; tomography; enhance ultrasound imaging |
| Cu2O@CaCO3/HA | Cu2O [ | Inhibit colorectal cancer distant metastasis and recurrence by immunotherapy | |
| NaGdF4/CaCO3 | NaGdF4 [ | Magnetic resonance imaging | |
| Intranasal | CaCO3/HA/Diethylaminoethyl-dextran | Zolpidem [ | Higher loading efficacy; |
| CaCO3/HA | Loperamide [ | Reduce the pain sensitivity, high efficiency |
Figure 8Applications of CaCO3 or alginate-based hydrogel carriers in drug delivery. (A) Oral drug delivery. Reproduced with permission from [223], Springer Nature, 2017; (B) colon-specific delivery. Reproduced with permission from [224], Elsevier, 2021; (C) transdermal drug delivery. Reproduced with permission from [225]. Elsevier, 2021; (D) ocular drug delivery. Reproduced with permission from [226]. Elsevier, 2013; (E) intravenous drug delivery. Reproduced with permission from [227]. Ivyspring International Publisher. 2019; (F) intranasal drug delivery. Reproduced with permission from [228], Taylor & Francis, 2021.
Various Alg-based hydrogel carriers used in drug delivery.
| Delivery Types | Carriers | Drug | Properties | Ref. |
|---|---|---|---|---|
| Oral | Kefiran-Alg gel microspheres | Ciprofloxacin | pH-responsive, sustained release and antimicrobial | [ |
| Ag-Alg | Tanic acid | Small size, slow drug release, antibacterial function of Ag ions | [ | |
| Ag-Alg | BSA | Remote release | [ | |
| Alg hydrogel/chitosan micelles | Emodin | Small size, pH-sensitive, and sustained release | [ | |
| Alg based-hydrogels | Diclofenac sodium | Semi-interpenetrating polymer network, pH-sensitive, colon-targeted, and antimicrobial | [ | |
| Alg/carboxymethyl chitosan composite gel beads | Bovine serum albumin | pH-sensitive, long swelling time and sustained release | [ | |
| Chitosan-Alg based microgel | polyphenols | pH-responsive, physicochemical stabilities and sustained release | [ | |
| Colon specific | Guar gum succinate-Alg beads | Ibuprofen | pH-dependent swelling behavior, almost no cytotoxicity | [ |
| Portulaca oleracea polysaccharide-Alg-borax hydrogel beads | 5-fluorouracil | pH responsive, for colorectal cancer | [ | |
| Alg-chitosan | Icariin | pH responsive and high retention in colon, anti-inflammatory, for colonic mucosal injury | [ | |
| Chitosan, nanocellulose and Alg based polymeric system | 5-Fluorouracil | pH dependent release and enzymatic degradation, for colon cancer | [ | |
| Transdermal | Alg hydrogels | Vitamin D3 | Highly porous (89.2 ± 12.5%) and biodegradable. Hemo- and cyto-compatible, for wound dressing | [ |
| Ca-Alg-PEGMA Hydrogels | Anti-TGF-β antibodies | High mechanical strength, biocompatible, and biodegradable, for wound healing | [ | |
| Chitosan/Alg hydrogels | Alpha-tocopherol | Biodegradable, for skin injuries | [ | |
| Gallic acid modified Alg | Caffeine | Highly porous and excellent elasticity | [ | |
| Alg/gum acacia hydrogels | ZnO2 nanoparticles | Biocompatible, antibacterial, anti-inflammatory, for wound healing | [ | |
| Silver nanoparticles | Sustained release and antibacterial, for wound dressing | [ | ||
| Intravenous | Fe3O4/polyethyleneimine/Alg | Fe3O4 | Enhanced magnetic resonance (MR) imaging | [ |
| Glycyrrhizin/Alg | Antioxidant quercetin | Improved liver targeting and therapeutic efficacy | [ | |
| Intranasal | Alg | Ropinirole hydrochloride | High encapsulation efficiency, safe to nasal epithelium. | [ |
| Lipopolysaccharide | Induce an effective systemic and mucosal immune response | [ | ||
| Alg/CS | PPE17 antigen | Induce strong immune response | [ |
Figure 9Schematic illustration of (A) preparation of INS-CaCO3 MPs through precipitation method in the presence of PVP as surfactant; (B) fabrication process of INS-CaCO3/PVP MNs from PMMA male mold, and (C) application of INS-CaCO3/PVP MNs on diabetic rats for transdermal delivery of insulin. Reproduced with permission from [248], Elsevier, 2018. (INS: insulin; MPs: microparticles; PVP: polyvinylpyrrolidone; MNs: microneedles; PDMS: Poly(dimethylsiloxane); PMMA: polymethyl methacrylate).
Summary of comparison of CaCO3, Alg, CaCO3/Alg carriers.
| CaCO3 (ACC and Vaterite) | Alg | CaCO3/Alg | |||
|---|---|---|---|---|---|
| Alg-Hs | Hollow Capsules | Alg Coated on CaCO3 | CaCO3 Embedded in Alg | ||
| Method | Facile, low-cost, eco-friendly, efficient, accessible | Facile, diverse, malleable, accessible | Facile, low-cost, eco-friendly, efficient, | ||
| Size | About 30 nm [ | Nano to millimeter [ | Determined by matrix | Determined by CaCO3 | Determined by Alg |
| Shape | Spherical and elliptical [ | Inconstant | |||
| Mechanism properties | Relatively high strength | Determined by the ratio of M/G [ | Harder than pure Alg | ||
| Loading capacity | Large molecules: up to 25% [ | Relatively lower than CaCO3 [ | Higher than CaCO3 and Alg, high encapsulation efficiency (up to 90%) [ | ||
| Release | pH dependent [ | Interface and concentration dependent [ | Synergistic effect; sustaining release [ | ||
| Application | Diverse drug delivery system; tissue engineering [ | Diverse drug delivery system, wound healing, tissue engineering [ | Diverse drug delivery system, tissue engineering, wound healing, bone regeneration [ | ||
Figure 10Various possibilities of combining CaCO3 particles and Alg, including (A) using CCPs as a template; (B) crosslinking Alg gels by a mineralization process; and (C) crosslinking Alg gels into a composite gel.
Hybrid carriers based on a combination of CaCO3 and Alg, their properties and applications.
| Applications | Carriers | Drugs or Test Objects | Properties |
|---|---|---|---|
| Drug delivery | CaCO3/Alg | Sorafenib tosylate/ Gold nanoparticles [ | High drug loading efficiency, controlled and sustainable release, high cell inhibition rate; |
| CaCO3/Alg+ | Indomethacin [ | ||
| Alg/Polyquaternium-10 (CaCO3 template) | Rhodamine B and 6-hydroxy | ||
| Alg/PSS/PAH | Rhodamine-labeled BSA [ | ||
| Tissue engineering | CaCO3/Alg | Alkaline phosphatase [ | Support osteoblast growth and new tissue formation, good cell adhesion and proliferation ability |
| Alg scaffolds | Dextran [ | ||
| Vascular imaging, ultrasound (US) imaging | CaCO3/Alg | BaSO4 [ | Good medical perfusion and angiography effects |